Zacks Research Forecasts Weaker Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research lowered their FY2026 earnings per share estimates for Avanos Medical in a research report issued on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the company will earn $1.99 per share for the year, down from their previous forecast of $2.00. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share.

Separately, StockNews.com cut shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Down 1.8 %

AVNS opened at $15.55 on Friday. The firm has a market cap of $714.63 million, a price-to-earnings ratio of 45.74 and a beta of 0.95. Avanos Medical has a twelve month low of $15.51 and a twelve month high of $25.36. The firm’s 50-day simple moving average is $18.33 and its 200-day simple moving average is $21.04. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Avanos Medical by 6.9% in the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company’s stock valued at $1,672,000 after acquiring an additional 4,472 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Avanos Medical by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock valued at $25,337,000 after acquiring an additional 16,065 shares during the period. Barclays PLC boosted its stake in Avanos Medical by 446.2% during the 3rd quarter. Barclays PLC now owns 96,194 shares of the company’s stock worth $2,311,000 after acquiring an additional 78,583 shares during the last quarter. Zacks Investment Management bought a new stake in Avanos Medical in the third quarter valued at approximately $335,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of Avanos Medical in the 3rd quarter valued at $212,000. Institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.